Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination.
Georg GelbeneggerFilippo CacioppoChrista FirbasBernd JilmaPublished in: Vaccines (2021)
We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis.
Keyphrases
- acute kidney injury
- sars cov
- coronavirus disease
- physical activity
- respiratory syndrome coronavirus
- protein kinase
- drug induced
- cardiac arrest
- skeletal muscle
- body mass index
- liver failure
- oxidative stress
- combination therapy
- high dose
- tyrosine kinase
- cardiopulmonary resuscitation
- hepatitis b virus
- metabolic syndrome
- depressive symptoms
- single cell
- replacement therapy
- mechanical ventilation
- electron transfer